Syngeneic acute myeloid leukaemia (AML) C1498 tumours responded to intravenous therapy with VSV-murine IFNβ (mIFNβ)-NIS in a dose-dependent manner. The gene discussed is SLC5A5; the disease is acute myeloid leukemia.